The impact of AID function in B cell neoplasia development has been addressed in a number of in vivo models, including IL6 [19], [21] and pristane [23] promoted plasmacytomas, BCL-6-induced diffuse large B cell lymphoma [22], Eμ-Myc model of B cell lymphoma [24] and a myc-induced multiple myeloma model [25]. This evidence concerns the gene MYC and B-cell non-Hodgkin lymphoma.